×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Track 1 Session 5: Oncology Therapeutics: Minimizing Risks for Maximum Benefit
Session Chair(s)
Ritu Jaswal
Vice President - Pharmacovigilance Operations
Parexel, India
Track 1 Session 5: Oncology Therapeutics: Minimizing Risks For Maximum Benefit
Speaker(s)
Oncology Therapeutics At Novartis
Anika Rana
Novartis, India
Head Medical Safety Assessment and ESP Engagement
Safety Profile/Risk Minimization Of Approved Chemotherapeutic Drugs
Naveen Chhabra
Novartis, India
Senior Medical Safety Lead
Risk Minimization For Developmental Oncology Drugs Including CAR-T And Radioligand Therapies
Ritu Singal
Novartis, India
Global Program Safety Lead
Learning From The Frontier: Risk Management In CAR-T Cell Immunotherapy For Haematological Malignancies
Anupam Chhabra
Immuneel Therapeutics Private Limited, India
Head of Medical Affairs
Have an account?